Nimacimab

尼迈西单抗

Report date: 2024/04/02 15:33:25

Base Information

Drug NameNimacimab
Drug Alias NameNamacizumabRYI-018RYI-028JNJ-2463
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionCannabinoid CB1 receptor antagonists
TargetsCannabinoid CB1 receptor
Therapy Area/IndicationsDiabetic GastroparesisObesityRenal Insufficiency, Chronic +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesAustralia
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesBird Rock Bio Inc
China Registration ClassN/A

Develop Information

Active CompaniesArecor Therapeutics PLCSkye Bioscience Inc
Inactive CompaniesBird Rock Bio Inc
Active IndicationsObesityRenal Insufficiency, Chronic
Inactive IndicationsDiabetic GastroparesisMetabolic Dysfunction-Associated Steatotic Liver Disease

Other Information

ATC CodeN/A
Related LinksN/A